Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

NCT06475820 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Biphenotypic Acute Leukemia
Malignant Lymphoma
Myelodysplastic Syndromes

Interventions

DRUG: Baricitinib

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology